Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis
A man sits in a dimly lit room, talking to a friend. He’s describing a life disrupted by alcohol. He’s one of the 14 million adults in the U.S. who live with alcohol use disorder (AUD). Current treatments often fail to stop the cycle of relapse, and now, psilocybin therapy is emerging as a possible alternative. But does it work? A recent meta-analysis of six clinical trials offers a glimpse, but also shows the limits of the current data.
Bottom line: Psilocybin-assisted therapy shows early signs of reducing alcohol consumption and increasing long-term abstinence, but more research is needed to confirm its role in treating AUD.

The Science Behind the Psychedelic Promise
Psilocybin, the active compound in magic mushrooms, has sparked renewed interest in treating AUD. Unlike traditional approaches like naltrexone or counseling, psilocybin therapy involves taking the drug in a controlled, supervised setting. The idea is that psilocybin might disrupt the thought patterns that keep people drinking.
In the meta-analysis, researchers looked at six clinical trials with 202 participants, three of which were randomized controlled trials. The results showed a reduction in alcohol consumption, including fewer drinks per day, fewer days drinking, and fewer heavy drinking days. These effects lasted for up to 28 weeks.
One finding was unexpected: patients were more likely to stay sober after treatment. Their odds of success were nearly three times higher than those in control groups. This hints that psilocybin may help patients achieve and keep sobriety, not just cut back on drinking.
But the studies varied in design, dosage, and support. Some used placebos, others compared psilocybin to standard care. This variation makes it hard to draw firm conclusions. More consistent, large-scale trials are needed.
The Mechanism: How Psilocybin Might Work
Psilocybin acts on the brain by binding to serotonin receptors, especially the 5-HT2A receptor. This interaction may break down entrenched behaviors and thoughts that drive addiction.
In AUD, psilocybin may help by reducing cravings and improving emotional awareness. Patients often report deep insights during sessions, which can change their views on addiction and motivate recovery. Some studies suggest it also promotes neuroplasticity—the brain’s ability to rewire itself. This could be important for AUD, where chronic drinking has long-term effects on the brain.
But the role of psychotherapy can’t be ignored. Many studies included guided sessions, where patients reflect and process their experiences. This combination of drug and therapy may be key to the benefits observed.
A Mixed Picture: What the Data Actually Shows
The evidence is promising but limited. Psilocybin showed some short-term benefit in reducing drinking, but long-term effects were less clear. Only one of the three RCTs found a significant reduction in drinking days at mid- to long-term follow-up.
The studies were small and varied in methods, which weakens the conclusions. One trial suggested that higher doses led to better outcomes, but this was based on a small sample and affected by missing data. Another found no difference in drinking or abstinence at six months. This shows the need for more consistent, larger trials.
Safety was better. Most adverse events were mild and short-lived. No serious complications were reported. But long-term safety is unknown. The psychological effects of repeated use are still unclear.
Frequently Asked Questions
Q: Is psilocybin-assisted therapy safe?
A: Yes, the studies found it was generally well-tolerated, with mild and transient adverse effects. No serious complications or deaths were reported, though long-term safety is still being studied.
Q: Can psilocybin help with long-term abstinence?
A: The evidence is promising but not certain. Psilocybin-treated patients had higher odds of staying sober, but more research is needed to know how long these effects last.
Q: How does psilocybin compare to other treatments for AUD?
A: It showed some short-term benefits, but the evidence is mixed. It may not be more effective than other treatments like counseling or medication, and its role in a comprehensive plan is unclear.
Q: Are there any risks associated with psilocybin therapy?
A: Risks are generally low, but they can include psychological distress, anxiety, and emotional overwhelm. These are usually managed in a controlled setting, but long-term effects are still unknown.
Q: How long does the effect of psilocybin last?
A: Effects lasted up to 28 weeks in the studies, but the long-term durability is still under investigation.
Sources
- ¶Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis
- ¶Psilocybin-assisted therapy for alcohol use disorder: A systematic review of randomized controlled trials
- ¶Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.